Kang Mee Joo, Park Eun Hye, Yun E Hwa, Kim Hye-Jin, Jung Kyu-Won, Park Sang-Jae
Korea Central Cancer Registry, National Cancer Center, Goyang, Korea.
Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Ann Hepatobiliary Pancreat Surg. 2025 Aug 31;29(3):209-217. doi: 10.14701/ahbps.25-135. Epub 2025 Jul 28.
BACKGROUNDS/AIMS: Biliary tract and pancreatic cancers remain leading contributors to cancer-related mortality in Korea, even though their incidence rates are comparatively low. This study evaluates long-term national patterns in these malignancies utilizing population-based data.
Information from the Korea Central Cancer Registry was used to assess 258,854 patients newly diagnosed with gallbladder (n = 52,712), extrahepatic bile duct (n = 76,787), and pancreatic (n = 129,355) cancers between 1999 and 2022.
During the period from 1999 to 2022, the crude incidence rates for gallbladder (2.8 to 5.6 per 100,000), extrahepatic bile duct (3.6 to 9.8), and pancreatic cancers (5.5 to 19.1) all showed an upward trend. For pancreatic cancer, the age-standardized incidence rate rose markedly (5.6 to 8.4), whereas it stabilized for extrahepatic bile duct cancer (3.7 to 3.8), and declined for gallbladder cancer (2.9 to 2.2). The distributions of localized and regional disease stages remained largely consistent throughout the study period. There was an increase in the proportion of patients undergoing surgical intervention within the first 4 months post-diagnosis for gallbladder (42.3% to 48.2%) and pancreatic cancer (22.5% to 23.7%), while this proportion slightly declined in extrahepatic bile duct cancer (47.8% to 46.0%). The overall 5-year relative survival rate improved significantly in gallbladder (21.9% to 32.1%) and pancreatic (8.6% to 15.5%) cancers, and showed a modest improvement in extrahepatic bile duct cancer (23.1% to 27.2%).
The crude incidence rates for gallbladder, extrahepatic bile duct, and pancreatic cancers have continuously risen in Korea. While survival rates have improved, the persistently high mortality rates highlight the critical need for earlier diagnosis and advancements in therapeutic approaches.
背景/目的：在韩国，尽管胆管癌和胰腺癌的发病率相对较低，但它们仍然是癌症相关死亡的主要原因。本研究利用基于人群的数据评估这些恶性肿瘤的长期全国模式。
利用韩国中央癌症登记处的信息，评估了1999年至2022年间新诊断出的258,854例胆囊癌（n = 52,712）、肝外胆管癌（n = 76,787）和胰腺癌（n = 129,355）患者。
在1999年至2022年期间，胆囊癌（每10万人中2.8至5.6例）、肝外胆管癌（3.6至9.8例）和胰腺癌（5.5至19.1例）的粗发病率均呈上升趋势。胰腺癌的年龄标准化发病率显著上升（5.6至8.4），而肝外胆管癌则稳定（3.7至3.8），胆囊癌下降（2.9至2.2）。在整个研究期间，局限性和区域性疾病阶段的分布基本保持一致。胆囊癌（42.3%至48.2%）和胰腺癌（22.5%至23.7%）在诊断后前4个月内接受手术干预的患者比例有所增加，而肝外胆管癌的这一比例略有下降（47.8%至46.）。胆囊癌（21.9%至32.1%）和胰腺癌（8.6%至15.5%）的总体5年相对生存率显著提高，肝外胆管癌也有适度改善（23.1%至27.2%）。
在韩国，胆囊癌、肝外胆管癌和胰腺癌的粗发病率持续上升。虽然生存率有所提高，但持续的高死亡率凸显了早期诊断和治疗方法进步的迫切需求。
